Project Grant R41AG082600

Award Date 7/1/23
Completion Date 12/31/24
Dollars Obligated $287K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,498,158.00 to Synaptic Health LLC to develop a novel closed-loop feedback neuromodulation system to improve slow wave sleep in Alzheimer's disease patients. The project aims to create a prototype device that can sense sleep architecture and provide peripheral neuromodulation stimulation to individuals over age 65 who are at elevated risk of Alzheimer's disease. The goal is to demonstrate that...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate memory reactivation during sleep in a mouse model of Alzheimer's disease (AD). The $132,705 award, spanning from September 1, 2024 to August 31, 2026, will enable the Icahn School of Medicine at Mount Sinai to use two-photon microscopy and electrophysiology to measure brain activity across wake and sleep states in AD model mice. The research aims to determine if...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $780,466 to quantify the integrity of sleep-dependent memory processing in pathological aging and Alzheimer's disease, with the goal of developing inexpensive electroencephalographic (EEG) wearable applications for monitoring brain health and detecting early neurodegenerative changes. The key products and services being delivered under this 5-year award, which began on December 15, 2024,...
This $817,357 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) aims to develop robust machine learning (ML) and computational tools for comprehensive behavioral and brain signal analysis in humanized Alzheimer's disease (AD) mouse models. The key products/services to be delivered include: Further validation of the researchers' "Variational Animal Motion Embedding" (VAME) ML platform for high-resolution behavioral segmentation and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $446,875 aims to investigate the potential pleotropic effect of genetic risk variants for Alzheimer's disease on sleep patterns. The primary objectives are to conduct bioinformatic analyses to identify shared causal genes between Alzheimer's disease and sleep duration/phenotypes, and to perform CRISPR studies in zebrafish to directly assess the impact of putative Alzheimer's disease risk...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $258,498.00 to the University of California, Los Angeles (UCLA) to investigate the biological pathways linking sleep health to Alzheimer's disease and cognitive decline. The key objectives are to: Use a multi-omics approach to analyze methylation and metabolomics data associated with short sleep and insomnia among a high-risk Hispanic population, and compare the results to Alzheimer's...
The National Institute on Aging (NIA) awarded Eyenexo LLC a $245,148 project grant under the Aging Research program (CFDA 93.866) to develop an automated rodent behavior testing system for assessing early Alzheimer's disease (AD). The system aims to leverage computer vision techniques to non-invasively monitor defensive behaviors in rodents, such as freezing and escape responses to looming stimuli, which have been shown to be affected early in the AD disease process. The 2-year project seeks...
This $1,955,041 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into the relationship between sleep, pericytes, and Alzheimer's disease pathology. The Medical University of South Carolina will investigate whether pericytes, cells that regulate cerebral blood flow and blood-brain barrier permeability, mediate the effects of sleep disruption on Alzheimer's disease progression. Specifically, the...
This National Science Foundation Project Grant of $255,851 awarded on September 15, 2022 will support the development of a neuromodulation device to promote healthy sleep cycles through the completion of prototype engineering. The awardee, Neurolight Inc. of Suffern, New York, will utilize controlled light and sound stimuli delivered via an externally worn system to transpose normal brain wave patterns associated with desired sleep states into recipients suffering from sleep disorders. This aims...
The National Institute on Aging (NIA) awarded a $454,024 Project Grant (CFDA 93.866 - Aging Research) to the Research Foundation For Mental Hygiene, Inc. (RFMH) to conduct research on high-frequency oscillations (HFOs) as a potential biomarker for Alzheimer's disease progression. The key goals of this 2-year project are to: (1) determine if HFOs originate in the hippocampus and expand to other brain regions as Alzheimer's pathology advances, (2) assess whether disrupting HFOs can improve...

NONINVASIVE SLEEP ENHANCEMENT AND BEHAVIOR MONITORING TECHNOLOGIES FOR ALZHEIMER'S MODEL MICE - THE AIMS OF THIS PROJECT ARE TO DEVELOP NEW TECHNOLOGIES TO IDENTIFY AND TRACK SLEEP AND WAKE ABNORMALITIES PRESENT IN MOUSE MODELS OF ALZHEIMER'S DISEASE (AD), AS WELL AS TO TEST A SLEEP ENHANCEMENT TECHNOLOGY FOR APPLICATIONS IN AD ANIMAL RESEARCH. SIGNAL SOLUTIONS, LLC, HAS PREVIOUSLY DEVELOPED AND COMMERCIALIZED A PIEZOELECTRIC BASED SYSTEM FOR NONINVASIVE, HIGH-THROUGHPUT SLEEP AND WAKE MONITORING OF RODENTS. AUTOMATED SCORING OF SLEEP AND WAKE ALLOWS FOR SIMULTANEOUS RECORDINGS OF MANY ANIMALS OVER LONGER PERIODS, WITH LITTLE BURDEN ON THE RESEARCHER, RIVALLING EEG/EMG METHODS THAT ARE MORE COMPLICATED AND EXPENSIVE TO PERFORM. BEHAVIORAL CHANGES IN SLEEP AND WAKE CAN PRECEDE MEMORY LOSS IN THE PROGRESSION OF ALZHEIMER'S DISEASE (AD). CLINICAL STUDIES SUGGEST SLEEP DISTURBANCES ARE EXHIBITED IN A HIGH PERCENTAGE OF AD PATIENTS. ANIMAL MODELS OF AD ALSO DISPLAY SLEEP DISTURBANCES AND SOME MODELS SHOW CHANGES IN WAKE BEHAVIORS BEFORE THE MOLECULAR HALLMARKS AND MEMORY PROBLEMS APPEAR, AS CLEARLY OCCURS IN HUMAN AD. IN THE TREATMENT OF AD, A POTENTIAL THERAPEUTIC TARGET IS PREVENTING THE AGGREGATION OF PATHOGENIC FORMS OF AMYLOID-BETA (A-BETA) AND TAU. WASTE CLEARANCE IN THE BRAIN HAS BEEN SHOWN TO BE INCREASED WITH INCREASED SLEEP, INCLUDING CLEARANCE OF A-BETA. RECENTLY, NON-PHARMACOLOGICAL APPROACHES USING MECHANICAL DEVICES FOR ROCKING HAVE SHOWN PROMISE FOR SLEEP ENHANCEMENT, WHICH COULD BE APPLIED TO AD RESEARCH. THE SPECIFIC AIMS OF THIS PROJECT ARE TO 1) DEVELOP ADVANCED SLEEP/WAKE TRACKING TECHNOLOGY: ADD A NEW MULTIPOINT TOUCH SENSOR TO OUR CURRENT PIEZOELECTRIC TECHNOLOGY THAT TOGETHER WILL IDENTIFY SPECIFIC BEHAVIORS ASSOCIATED WITH AD PROGRESSION, TESTED WITH AD MOUSE MODEL 3XTG. 2) DEVELOP SLEEP ENHANCEMENT TECHNOLOGY: MODIFY OUR CURRENT MOUSEQWAKE SLEEP-DISRUPTION SYSTEM FOR MECHANICAL SLEEP-ENHANCEMENT, WITH COMPANION SLEEP AND WAKE TRACKING CAPABILITIES. ANTICIPATED OUTCOMES: THE ENVISIONED PRODUCT IS A HOME CAGE SENSOR AND SOFTWARE THAT WILL ALLOW RESEARCHERS TO ACCURATELY MEASURE CHANGES IN SLEEP AND WAKE DURING LONG-TERM AD DISEASE PROGRESSION, AS WELL AS TRACK SUBTLE CHANGES IN BEHAVIOR IN AD MODEL MICE. THIS SYSTEM WILL MINIMIZE THE AMOUNT OF WORK, TIME TESTING BEHAVIORS, AND TIME FOR ANALYZING THE VIDEOS OR ELECTROPHYSIOLOGY THAT IS CURRENTLY A MAJOR BOTTLENECK. AN EXPANDED MOUSEQWAKE SYSTEM WILL PROVIDE A TOOL FOR SLEEP MANIPULATION OF BOTH SLEEP ENHANCEMENT AND DISRUPTION AS WELL AS SIMULTANEOUS SLEEP/WAKE AND BEHAVIORAL RECORDING. IF SUCCESSFUL, A PHASE II INVESTIGATION WILL INVOLVE LARGE SCALE STUDIES OF MULTIPLE AD RODENT MODELS, AND CONTINUE ITERATIVE IMPROVEMENTS TO BOTH HARDWARE AND SOFTWARE DEVELOPED IN PHASE I.

Posted 6/9/23, 12:00 AM